MedTrace Logo

Pleotropic Effect of New Oral Anticoagulants

NCT02544932 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2015-09-09

No results posted yet for this study

Summary

Atrial fibrillation (AF) has been known to have several pathophysiologic mechanisms including endothelial dysfunction of heart and vessel. This study was designed to determine the efficacy of NOAC therapy in the prevention of endothelial dysfunction and progression of atherosclerosis of AF subjects.

Conditions

Interventions

DRUG

dabigatran

After randomization, patients of this group was will be treated to dabigatran 110mg or 150mg twice a day for 24months

DRUG

ribaroxaban

After randomization, patients of this group was will be treated to ribaroxaban 20mg once a day for 24months.

DRUG

Warfarin

After randomization, patients of this group was will be treated to warfarin and controlled by INR 2-3 for 24months.

Sponsors & Collaborators

  • Kyunghee University Medical Center

    lead OTHER

Principal Investigators

  • Weon Kim, MD, PhD · Kyunghee University Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-10-31
Primary Completion
2017-09-30
Completion
2017-09-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02544932 on ClinicalTrials.gov